Both nusinersen and tofersen, approved ASO drugs for the treatment of spinal muscular atrophy and SOD1-driven ALS, respectively, are administered directly to the CNS through intrathecal infusions. The gene discussed is SOD1; the disease is spinal muscular atrophy.